Literature DB >> 3893567

Pre-B cells in peripheral blood of multiple myeloma patients.

L M Pilarski, M J Mant, B A Ruether.   

Abstract

Although multiple myeloma is a disease of plasma cells, abnormalities have been detected in both B and T lymphocytes in peripheral blood. Although multiple myeloma patients are deficient in surface Ig (sIg)-positive B lymphocytes, analysis of lymphocytes present in blood indicates an abnormally large pool of circulating pre-B cells. These pre-B cells express BA-1, do not bear sIg, and contain cytoplasmic mu chains. High numbers of pre-B cells occur in 88% of individuals with frank myeloma and in 44% of individuals with monoclonal gammopathy of undetermined significance. Pre-B cells bearing BA-1 differ between patients in their expression of HLA-DR and receptors for peanut agglutinin (PNA). Those pre-B cells in myeloma patients are either BA-1+ PNA- HLA-DR+ (54% of patients) or BA-1+ PNA+ HLA-DR- (30% of patients), or have a mixture of phenotypes (14% of patients). Pre-B cells of the PNA- phenotype are almost always HLA-DR+, and PNA+ pre-B cells are HLA-DR-. Within the same patient, the pre-B cell population varies by both quantitative and qualitative definitions. The number of pre-B cells may increase 460-fold and temporal shifts of surface phenotype from BA-1+ PNA- to BA-1+ PNA+ or vice versa have been detected. These observations indicate an abnormality in the B lymphocyte differentiation pathway leading to pre-B cells in the periphery that vary in number and cell surface phenotype, and that are unable to express sIg.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893567

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies.

Authors:  P L Tazzari; M Gobbi; A Dinota; A Bontadini; G Grassi; C Cerato; M Cavo; S Pileri; F Caligaris-Cappio; S Tura
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

3.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

4.  Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).

Authors:  D M Menke; H P Horny; H Griesser; E J Atkinson; E Kaiserling; R A Kyle
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

5.  Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma.

Authors:  X G Zhang; B Klein; C Duperray; J Brochier; R Bataille
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

6.  Specificity repertoire of lymphocytes from multiple myeloma patients. I. High frequency of B cells specific for idiotypic and F(ab')2-region determinants on immunoglobulin.

Authors:  L M Pilarski; M Piotrowska-Krezolak; D J Gibney; L Winger; C Winger; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

7.  Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients.

Authors:  H M Serra; M J Mant; B A Ruether; J A Ledbetter; L M Pilarski
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

8.  A prognostic index for multiple myeloma.

Authors:  G Grignani; P G Gobbi; R Formisano; C Pieresca; G Ucci; S Brugnatelli; A Riccardi; E Ascari
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.